CAJ | 학술논문

目的：系统性分析 KRAS 和 EGFR 基因突变情况及与临床病理资料的相关性。方法利用PCR扩增及基因测序法检测199例非小细胞肺癌（NSCLC）患者KRAS基因第2、3外显子及EGFR基因18～21外显子的突变情况。结果（1）199例NSCLC患者中，KRAS基因突变率为5.03%。（2）KRAS基因在男性和女性NSCLC患者中的突变率分别为5.31%和4.65%；在肺腺癌和肺鳞癌患者中的突变率分别为5.30%和4.17%；在吸烟和非吸烟的患者中的突变率分别为5.26%和4.81%。（3）EGFR 基因突变率为47.24%。EGFR突变率在男、女性患者中分别为38.94%和58.14%；在腺癌和鳞癌中分别为54.30%和25.00%；在吸烟和非吸烟患者中分别为40.00%和53.85%。（4）KRAS基因在EGFR基因突变型和EGFR基因野生型的患者中的突变率分别为3.19%和6.60%。KRAS基因在EGFR基因突变型腺、鳞癌患者中突变率为2.44%和8.33%，在EGFR基因野生型腺、鳞癌患者中突变率为8.70%和2.78%；KRAS基因在EGFR基因突变型吸烟和非吸烟患者中突变率为2.63%和3.57%，在EGFR基因野生型吸烟和非吸烟患者中突变率为7.01%和6.25%。结论患者 KRAS 基因突变与患者的性别、病理类型及 EGFR 基因突变情况有一定的联系。在使用TKI靶向药之前，NSCLC患者应同时检测EGFR基因和KRAS基因的突变情况。
목적：계통성분석 KRAS 화 EGFR 기인돌변정황급여림상병리자료적상관성。방법이용PCR확증급기인측서법검측199례비소세포폐암（NSCLC）환자KRAS기인제2、3외현자급EGFR기인18～21외현자적돌변정황。결과（1）199례NSCLC환자중，KRAS기인돌변솔위5.03%。（2）KRAS기인재남성화녀성NSCLC환자중적돌변솔분별위5.31%화4.65%；재폐선암화폐린암환자중적돌변솔분별위5.30%화4.17%；재흡연화비흡연적환자중적돌변솔분별위5.26%화4.81%。（3）EGFR 기인돌변솔위47.24%。EGFR돌변솔재남、녀성환자중분별위38.94%화58.14%；재선암화린암중분별위54.30%화25.00%；재흡연화비흡연환자중분별위40.00%화53.85%。（4）KRAS기인재EGFR기인돌변형화EGFR기인야생형적환자중적돌변솔분별위3.19%화6.60%。KRAS기인재EGFR기인돌변형선、린암환자중돌변솔위2.44%화8.33%，재EGFR기인야생형선、린암환자중돌변솔위8.70%화2.78%；KRAS기인재EGFR기인돌변형흡연화비흡연환자중돌변솔위2.63%화3.57%，재EGFR기인야생형흡연화비흡연환자중돌변솔위7.01%화6.25%。결론환자 KRAS 기인돌변여환자적성별、병리류형급 EGFR 기인돌변정황유일정적련계。재사용TKI파향약지전，NSCLC환자응동시검측EGFR기인화KRAS기인적돌변정황。
Objective To analysis the correlation of the KRAS gene mutation with the EGFR gene mutation and the clinical data in non-small cell lung cancer(NSCLC). Methods 199 NSCLC cases were evaluated the mutation status of the exon 2 and 3 of the KRAS gene and the exons 18-21 of the EGFR gene by PCR amplification followed by direct sequencing. Results (1) In 199 of NSCLC patients, the mutation rate of the KRAS gene was 5.03%. (2) The mutation rates of the KRAS gene in male and female patients were 5.31%and 4.65%, respectively. The mutation rates of the KRAS gene in adenocarcinoma and squamous carcinoma patients were 5.30%and 4.17%, respectively. The mutation rates of the KRAS gene in patients with smoking history and without smoking history were 5.26% and 4.81%, respectively. (3) The mutation rate of the EGFR gene was 47.24%. The EGFR gene mutation rates in male and female NSCLC patients were 38.94% and 58.14%. The mutation rates of the EGFR gene in adenocarcinoma and squamous carcinoma patients were 54.30%and 25.00%. The mutation rates of the EGFR gene in smokers and nonsmokers patients were 40.00% and 53.85%. (4) The mutation rates of the KRAS gene in EGFR mutation-positive and EGFR mutation-negative patients were 3.19%and 6.60%. Among the EGFR mutation-positive patients, the mutation rates of the KRAS gene in adenocarcinoma and squamous carcinoma were 2.44%and 8.33%. Among the EGFR mutation-negative patients, the mutation rates of the KRAS gene in adenocarcinoma and squamous carcinoma were 8.70% and 2.78%. Among the EGFR mutation-positive patients, the mutation rates of the KRAS gene in smokers and non-smokers were 2.63% and 3.57%. Among the EGFR mutation-negative patients, the mutation rates of the KRAS gene in smokers and non-smokers were 7.01% and 6.25%. Conclusion KRAS mutation tends to correlate with sex, pathology and EGFR gene mutation. The patients of NSCLC should evaluate the mutation status of EGFR gene and KRAS gene before TKI therapy.